Structures by: Essassi E. M.
Total: 358
Dimethyl 3-acetyl-3-(1,3-benzothiazol-2-yl)pentanedioate
C16H17NO5S
Acta Crystallographica Section E (2008) 64, 12 o2290
a=14.4075(3)Å b=8.8089(2)Å c=13.8968(3)Å
α=90.00° β=118.0110(10)° γ=90.00°
6-Methyl-7,7,9-tripropargyl-7<i>H</i>-1,2,4- triazolo[4,3-<i>b</i>][1,2,4]triazepin-8(9<i>H</i>)-one
C15H13N5O
Acta Crystallographica Section E (2009) 65, 9 o2148
a=7.6710(2)Å b=8.2415(2)Å c=12.9619(3)Å
α=108.5100(10)° β=90.6590(10)° γ=114.7260(10)°
1-Benzyl-3-[(dimethylamino)methylene]-4-phenyl-1<i>H</i>- 1,4-benzodiazepin-2(3<i>H</i>)-one
C25H23N3O
Acta Crystallographica Section E (2009) 65, 9 o2160
a=8.9733(3)Å b=26.3103(7)Å c=9.9312(3)Å
α=90° β=115.6440(10)° γ=90°
7,9-Diallyl-6-methyl-7<i>H</i>-1,2,4-triazolo[4,3-<i>b</i>][1,2,4]triazepin-\ 8(9<i>H</i>)-one
C12H15N5O
Acta Crystallographica Section E (2009) 65, 9 o2152
a=7.4674(3)Å b=8.3398(3)Å c=20.2214(6)Å
α=90.00° β=95.174(2)° γ=90.00°
3-Methyl-1-propargylquinoxalin-2(1<i>H</i>)-one
C12H10N2O
Acta Crystallographica Section E (2009) 65, 9 o2196
a=21.1240(10)Å b=4.3709(2)Å c=22.2460(10)Å
α=90.00° β=105.354(6)° γ=90.00°
5-Methyl-3-[1-(2-pyridylmethyl)-1<i>H</i>-benzimidazol-2-ylmethyl]isoxazole
C18H16N4O
Acta Crystallographica Section E (2009) 65, 11 o2714-o2715
a=11.0761(2)Å b=8.65350(10)Å c=16.5920(3)Å
α=90.0° β=103.1360(10)° γ=90.0°
3-[2-(3-Methyl-2-oxo-1,2-dihydroquinoxalin-1-yl)ethyl]oxazolidin-2-one
C14H15N3O3
Acta Crystallographica Section E (2009) 65, 8 o2024-o2025
a=12.280(3)Å b=10.736(3)Å c=20.406(4)Å
α=90° β=102.320(10)° γ=90°
1-Allyl-4-phenyl-2,3-dihydro-1<i>H</i>-1,5-benzodiazepin-2-one
C18H16N2O
Acta Crystallographica Section E (2010) 66, 6 o1277
a=11.4863(3)Å b=6.0053(2)Å c=20.3667(5)Å
α=90.00° β=93.5250(10)° γ=90.00°
1-(1-Nonyl-2-oxoindolin-3-ylidene)thiosemicarbazide
C18H26N4OS
Acta Crystallographica Section E (2010) 66, 6 o1332
a=11.5343(2)Å b=10.5921(2)Å c=15.6262(3)Å
α=90.00° β=95.9220(10)° γ=90.00°
1-(1-Decyl-2-oxoindolin-3-ylidene)thiosemicarbazide
C19H28N4OS
Acta Crystallographica Section E (2010) 66, 6 o1333
a=11.8856(2)Å b=11.0055(2)Å c=15.1638(3)Å
α=90.00° β=99.4680(10)° γ=90.00°
1-Tetradecylindoline-2,3-dione
C22H33NO2
Acta Crystallographica Section E (2010) 66, 6 o1410
a=27.6647(8)Å b=4.70550(10)Å c=15.7583(5)Å
α=90.00° β=103.6350(10)° γ=90.00°
1-Decylindoline-2,3-dione
C18H25NO2
Acta Crystallographica Section E (2010) 66, 6 o1411
a=22.7208(3)Å b=4.71890(10)Å c=15.82540(10)Å
α=90.00° β=106.8270(10)° γ=90.00°
Ethyl {4-[(1,5-dimethyl-2,4-dioxo-2,3,4,5-tetrahydro-1<i>H</i>-1,5- benzodiazepin-3-yl)methyl]-1,2,3-triazol-1-yl}acetate
C18H21N5O4
Acta Crystallographica Section E (2010) 66, 11 o3039
a=8.5452(2)Å b=15.9993(5)Å c=13.9215(4)Å
α=90.00° β=106.8530(10)° γ=90.00°
3-[(1-Benzyl-1<i>H</i>-1,2,3-triazol-5-yl)methyl]-6-bromo-2-phenyl- 3<i>H</i>-imidazo[4,5-<i>b</i>]pyridine
C22H17BrN6
Acta Crystallographica Section E (2011) 67, 4 o890-o891
a=41.122(6)Å b=5.8358(10)Å c=15.988(3)Å
α=90° β=93.922(6)° γ=90°
Methyl 2-(3-oxo-3,4-dihydro-2<i>H</i>-1,4-benzothiazin-4-yl)acetate
C11H11NO3S
Acta Crystallographica Section E (2011) 67, 3 o724
a=17.347(5)Å b=8.724(2)Å c=7.2740(10)Å
α=90.00° β=98.71(2)° γ=90.00°
1,3-Dimethyl-3-tetradecyl-1<i>H</i>-1,5-benzodiazepine- 2,4(3<i>H</i>,5<i>H</i>)-dione
C25H40N2O2
Acta Crystallographica Section E (2011) 67, 3 o674
a=8.12860(10)Å b=33.5899(5)Å c=9.4095(2)Å
α=90.00° β=114.6400(10)° γ=90.00°
3-{[3-(4-Chlorophenyl)-4,5-dihydro-1,2-oxazol-5-yl]methyl}-1,5-dimethyl- 1<i>H</i>-1,5-benzodiazepine-2,4(3<i>H</i>,5<i>H</i>)-dione
C21H20ClN3O3
Acta Crystallographica Section E (2011) 67, 3 o720
a=8.18210(10)Å b=9.07410(10)Å c=13.3792(2)Å
α=79.7480(10)° β=80.1420(10)° γ=85.9100(10)°
5-Nitro-1-nonyl-1<i>H</i>-benzimidazol-2(3<i>H</i>)-one
C16H23N3O3
Acta Crystallographica Section E (2011) 67, 3 o669
a=5.4830(10)Å b=10.2092(15)Å c=14.746(3)Å
α=74.275(9)° β=79.727(6)° γ=83.410(8)°
3-[2-(3-Methylquinoxalin-2-yloxy)ethyl]-1,3-oxazolidin-2-one
C14H15N3O3
Acta Crystallographica Section E (2010) 66, 5 o1050
a=6.9936(3)Å b=7.6916(3)Å c=13.3709(6)Å
α=86.649(2)° β=77.044(2)° γ=71.141(2)°
(<i>E</i>)-4-(2,3-Dihydro-1,3-benzothiazol-2-ylidene)-3-methyl-1-phenyl- 1<i>H</i>-pyrazol-5(4<i>H</i>)-one
C17H13N3OS
Acta Crystallographica Section E (2010) 66, 5 o1096
a=27.0144(8)Å b=7.4021(2)Å c=14.0523(4)Å
α=90.00° β=97.4660(10)° γ=90.00°
3-Methyl-1-(prop-2-en-1-yl)quinoxalin-2(1<i>H</i>)-one
C12H12N2O
Acta Crystallographica Section E (2010) 66, 7 o1767
a=5.0722(5)Å b=13.4707(13)Å c=15.0507(13)Å
α=90.00° β=95.082(5)° γ=90.00°
3-[2-(5<i>H</i>-Indolo[2,3-<i>b</i>]quinoxalin-5-yl)ethyl]-1,3-oxazolidin-2-one
C19H16N4O2
Acta Crystallographica Section E (2010) 66, 9 o2461
a=14.5565(4)Å b=5.8993(2)Å c=18.6434(6)Å
α=90.00° β=92.393(2)° γ=90.00°
1-Nonyl-1<i>H</i>-benzimidazol-2(3<i>H</i>)-one
C16H24N2O
Acta Crystallographica Section E (2011) 67, 2 o283
a=18.0230(10)Å b=5.4585(2)Å c=16.5708(9)Å
α=90.00° β=115.543(7)° γ=90.00°
1,3-Bis[2-(2-oxo-1,3-oxazolidin-3-yl)ethyl]-1<i>H</i>-benzimidazol- 2(3<i>H</i>)-one
C17H20N4O5
Acta Crystallographica Section E (2011) 67, 2 o362-o363
a=10.5331(10)Å b=10.9647(10)Å c=14.5541(14)Å
α=90° β=103.258(5)° γ=90°
4-Phenyl-9,12,15-trioxa-1,5,6,18- tetraazatetracyclo[16.6.1.0^2,6^.0^19,24^]pentaconta-2,4,19,21,23- pentaen-25-one
C24H26N4O4
Acta Crystallographica Section E (2009) 65, 10 o2493
a=13.3480(10)Å b=15.7850(10)Å c=11.0070(10)Å
α=90° β=102.6810(10)° γ=90°
1,3-Diallyl-2-methylbenzimidazolium bromide dihydrate
C14H17N2,Br,2H2O
Acta Crystallographica Section E (2009) 65, 10 o2321
a=13.2888(2)Å b=16.8763(2)Å c=7.38970(10)Å
α=90.00° β=109.7730(10)° γ=90.00°
\ 10-Allyl-2,3-dihydro-1<i>H</i>-pyrrolo[2,1-<i>c</i>][1,4]benzodiazepine-5,\ 11(10<i>H</i>,11a<i>H</i>)-dione
C15H16N2O2
Acta Crystallographica Section E (2009) 65, 10 o2322
a=7.09880(10)Å b=11.7166(2)Å c=15.6592(3)Å
α=90.00° β=90.00° γ=90.00°
1-Methyl-3-phenylquinoxalin-2(1<i>H</i>)-one
C15H12N2O
Acta Crystallographica Section E (2009) 65, 10 o2323
a=16.3919(5)Å b=7.0775(2)Å c=20.0214(6)Å
α=90.00° β=95.434(2)° γ=90.00°
1-Allyl-3-chloro-6-nitro-1<i>H</i>-indazole
C10H8ClN3O2
Acta Crystallographica Section E (2009) 65, 10 o2320
a=7.68040(10)Å b=9.9559(2)Å c=28.4344(4)Å
α=90° β=95.1440(10)° γ=90°
1-Benzyl-3-phenylquinoxalin-2(1<i>H</i>)-one
C21H16N2O
Acta Crystallographica Section E (2009) 65, 11 o2685
a=5.4776(2)Å b=12.7015(3)Å c=12.7469(4)Å
α=62.260(2)° β=89.963(2)° γ=87.845(2)°
10,10'-Methylenebis[2,3-dihydro-1<i>H</i>- benzo[<i>e</i>]pyrrolo[1,2-<i>a</i>][1,4]diazepine- 5,11(10<i>H</i>,11a<i>H</i>)-dione] dihydrate
C25H24N4O4,2(H2O)
Acta Crystallographica Section E (2009) 65, 11 o2684
a=11.9901(2)Å b=11.9901Å c=13.6054(2)Å
α=90° β=90° γ=120°
1-Acetyl-4-phenyl-5a,6,7,8,9,9a-hexahydro-5<i>H</i>- 1,5-benzodiazepin-2(1<i>H</i>)-one
C17H20N2O2
Acta Crystallographica Section E (2009) 65, 11 o2657
a=9.6794(2)Å b=14.0095(3)Å c=11.2832(2)Å
α=90° β=98.0530(10)° γ=90°
4-[(1,5-Dibenzyl-2,4-dioxo-2,3,4,5-tetrahydro-1<i>H</i>-1,5-benzodiazepin- 3-yl)methyl]-1-<i>n</i>-octyl-1<i>H</i>-1,2,3-triazole
C34H39N5O2
Acta Crystallographica Section E (2010) 66, 1 o231
a=9.1797(2)Å b=10.4238(2)Å c=31.4716(7)Å
α=90.00° β=90.00° γ=90.00°
1-(12-Azido-<i>n</i>-dodecyl)-4-[(1,5-dibenzyl-2,4-dioxo-2,3,4,5-tetrahydro-\ 1<i>H</i>-1,5-benzodiazepin-3-yl)methyl]-1<i>H</i>-1,2,3-triazole
C38H46N8O2
Acta Crystallographica Section E (2010) 66, 1 o232
a=9.4269(2)Å b=12.3304(3)Å c=15.5500(4)Å
α=101.121(2)° β=92.175(2)° γ=92.935(2)°
Ethyl 2-{4-[(1,5-dibenzyl-2,4-dioxo-2,3,4,5-tetrahydro-1<i>H</i>-1,5- benzodiazepin-3-yl)methyl]-1<i>H</i>-1,2,3-triazol-1-yl}acetate
C30H29N5O4
Acta Crystallographica Section E (2010) 66, 1 o126
a=14.2015(5)Å b=10.9337(4)Å c=17.9368(6)Å
α=90.00° β=95.699(2)° γ=90.00°
3-[2-(2,3-dioxoindolin-1-yl)ethyl]-1,3-oxazolidin-2-one
C13H12N2O4
Acta Crystallographica Section E (2010) 66, 2 o454
a=7.1198(2)Å b=7.4694(2)Å c=12.0319(3)Å
α=83.338(2)° β=79.084(2)° γ=81.372(2)°
1,3-Dibenzyl-2-methylbenzimidazolium chloride
C22H21N2,Cl
Acta Crystallographica Section E (2010) 66, 2 o455
a=9.2539(2)Å b=9.4677(2)Å c=12.0984(3)Å
α=72.1390(10)° β=81.3760(10)° γ=64.6050(10)°
6-Bromo-1-[2-(2-oxo-1,3-oxazolidin-3-yl)ethyl]-1<i>H</i>- imidazo[4,5-<i>b</i>]pyridin-2(3<i>H</i>)-one
C11H11BrN4O3
Acta Crystallographica Section E (2010) 66, 2 o456
a=27.0174(11)Å b=6.0141(2)Å c=16.6121(6)Å
α=90.00° β=110.343(2)° γ=90.00°
3-(Phenylimino)indolin-2-one
C14H10N2O
Acta Crystallographica Section E (2010) 66, 2 o453
a=20.1647(4)Å b=5.02230(10)Å c=21.8791(5)Å
α=90.00° β=90.00° γ=90.00°
3-[(1-Benzyl-1<i>H</i>-1,2,3-triazol-4-yl)methyl]-1,5-dimethyl- 1,5-benzodiazepine-2,4-dione
C21H21N5O2
Acta Crystallographica Section E (2010) 66, 3 o632
a=8.3380(3)Å b=9.1033(3)Å c=13.4796(4)Å
α=95.385(2)° β=107.840(2)° γ=101.768(2)°
3-[(1-Benzyl-1<i>H</i>-1,2,3-triazol-5-yl)methyl]-1,5-dimethyl- 1,5-benzodiazepine-2,4-dione monohydrate
C21H21N5O2,H2O
Acta Crystallographica Section E (2010) 66, 3 o633
a=9.60020(10)Å b=11.9497(2)Å c=17.0860(2)Å
α=90.00° β=92.5270(10)° γ=90.00°
2-Hydroxy-10-propargylpyrrolo[2,1-<i>c</i>][1,4]benzodiazepine-5,11-dione monohydrate
C15H14N2O3,H2O
Acta Crystallographica Section E (2010) 66, 4 o731
a=6.89770(10)Å b=7.97610(10)Å c=13.0680(2)Å
α=90.00° β=99.1940(10)° γ=90.00°
2-Hydroxy-10-phenacylpyrrolo[2,1-<i>c</i>][1,4]benzodiazepine-5,11-dione
C20H18N2O4
Acta Crystallographica Section E (2010) 66, 4 o732
a=8.8337(2)Å b=9.9476(2)Å c=18.9295(4)Å
α=90.00° β=90.00° γ=90.00°
Ethyl 2-hydroxy-5,11-dioxopyrrolo[2,1-<i>c</i>][1,4]benzodiazepine-10-acetate
C16H18N2O5
Acta Crystallographica Section E (2010) 66, 4 o733
a=8.5503(2)Å b=9.6580(2)Å c=18.2734(4)Å
α=90.00° β=90.00° γ=90.00°
2-Methyl-3-(<i>n</i>-octylsulfanyl)quinoxaline
C17H24N2S
Acta Crystallographica Section E (2010) 66, 4 o992
a=7.3514(3)Å b=8.2978(3)Å c=14.2168(5)Å
α=92.275(2)° β=98.706(2)° γ=103.810(2)°
<i>N</i>-(5-Phenyl-1<i>H</i>-pyrazol-3-yl)benzene-1,2-diamine
C15H14N4
Acta Crystallographica Section E (2010) 66, 4 o841
a=13.2357(8)Å b=5.8473(4)Å c=16.4039(10)Å
α=90.00° β=92.074(4)° γ=90.00°
6-Bromo-1-(1,2-propadienyl)-3-(2-propynyl)-1<i>H</i>- imidazo[4,5-<i>b</i>]pyridin-2(3<i>H</i>)-one
C12H8BrN3O
Acta Crystallographica Section E (2010) 66, 4 o755
a=9.6369(4)Å b=9.3086(4)Å c=13.5481(5)Å
α=90.00° β=99.123(2)° γ=90.00°
6-Bromo-1,3-di-2-propynyl-1<i>H</i>-imidazo[4,5-<i>b</i>]pyridin- 2(3<i>H</i>)-one
C12H8BrN3O
Acta Crystallographica Section E (2010) 66, 4 o756
a=9.0725(3)Å b=18.6212(5)Å c=7.0684(2)Å
α=90.00° β=102.9950(10)° γ=90.00°
3-(Benzothiazol-2-yl)-3-(prop-2-ynyl)hex-5-yn-2-one
C16H13NOS
Acta Crystallographica Section E (2010) 66, 4 o857
a=7.79130(10)Å b=30.2051(6)Å c=12.4437(2)Å
α=90.00° β=106.1610(10)° γ=90.00°
4-Benzyl-6-bromo-2-phenyl-4<i>H</i>-imidazo[4,5-<i>b</i>]pyridine
C19H14BrN3
Acta Crystallographica Section E (2010) 66, 4 o946
a=8.6613(6)Å b=19.7631(13)Å c=9.3683(6)Å
α=90.00° β=99.647(3)° γ=90.00°
4-Benzyl-6-bromo-2-(4-methoxyphenyl)-4<i>H</i>-imidazo[4,5-<i>b</i>]pyridine monohydrate
C20H16BrN3O,H2O
Acta Crystallographica Section E (2010) 66, 4 o947
a=10.5924(2)Å b=5.45440(10)Å c=31.7444(7)Å
α=90.00° β=100.2920(10)° γ=90.00°
6-Bromo-3-methyl-1<i>H</i>-imidazo[4,5-<i>b</i>]pyridin-2(3<i>H</i>)-one
C7H6BrN3O
Acta Crystallographica Section E (2010) 66, 5 o1080
a=4.41510(10)Å b=9.6004(2)Å c=10.5330(3)Å
α=116.2480(10)° β=93.074(2)° γ=91.6870(10)°
1-Benzyl-3-[(dimethylamino)methylene]-4-phenyl-1<i>H</i>-1,5-benzodiazepine- 2(3<i>H</i>)-thione
C25H23N3S
Acta Crystallographica Section E (2010) 66, 5 o1019
a=26.4740(8)Å b=10.2366(2)Å c=16.5650(5)Å
α=90.00° β=106.1360(10)° γ=90.00°
8-Bromo-3,4-dihydro-2<i>H</i>1,3-thiazino[2,3:2',1']imidazo[5',4'- <i>b</i>]pyridine
C9H8BrN3S
Acta Crystallographica Section E (2010) 66, 5 o1079
a=20.2738(3)Å b=13.2786(2)Å c=7.31690(10)Å
α=90.00° β=102.1930(10)° γ=90.00°
3,4-Dimethyl-1<i>H</i>-1,2,4-triazepino[2,3-<i>a</i>]benzimidazol- 2(3<i>H</i>)-one
C12H12N4O
Acta Crystallographica Section E (2010) 66, 5 o1093
a=7.2899(3)Å b=14.4888(5)Å c=10.9932(4)Å
α=90.00° β=104.3140(10)° γ=90.00°
1-Isopropenyl-1<i>H</i>-1,3-benzimidazol-2(3<i>H</i>)-one
C10H10N2O
Acta Crystallographica Section E (2010) 66, 6 o1409
a=15.8724(2)Å b=6.09710(10)Å c=17.9313(3)Å
α=90.00° β=90.961(2)° γ=90.00°
4-Methyl-2,3-dihydro-1<i>H</i>-1,5-benzodiazepin-2-one monohydrate
C10H10N2O,H2O
Acta Crystallographica Section E (2010) 66, 6 o1408
a=4.90130(10)Å b=7.31480(10)Å c=13.5688(2)Å
α=85.3750(10)° β=83.9590(10)° γ=83.8070(10)°
3-Benzyl-6-bromo-2-(2-furyl)-3<i>H</i>-imidazo[4,5-<i>b</i>]pyridine
C17H12BrN3O
Acta Crystallographica Section E (2010) 66, 7 o1874
a=15.8422(3)Å b=5.47470(10)Å c=18.4243(3)Å
α=90.00° β=111.5090(10)° γ=90.00°
1,5-Dimethyl-3-propargyl-1<i>H</i>-1,5-benzodiazepine- 2,4(3<i>H</i>,5<i>H</i>)-dione
C14H14N2O2
Acta Crystallographica Section E (2010) 66, 7 o1797
a=16.0768(3)Å b=17.1087(3)Å c=8.9530(2)Å
α=90.00° β=93.7010(10)° γ=90.00°
Pyrrolo[2,1-<i>c</i>][1,4]benzodiazepine-5,11-dithione
C12H12N2S2
Acta Crystallographica Section E (2010) 66, 7 o1653
a=13.9831(5)Å b=10.0134(3)Å c=8.2670(3)Å
α=90.00° β=97.0890(10)° γ=90.00°
4-Allyl-6-bromo-2-phenyl-4<i>H</i>-imidazo[4,5-<i>b</i>]pyridine monohydrate
C15H12BrN3,H2O
Acta Crystallographica Section E (2010) 66, 8 o1903
a=7.43630(10)Å b=9.42380(10)Å c=11.0829(2)Å
α=68.0760(10)° β=74.6370(10)° γ=79.7360(10)°
6-Bromo-1,3-dimethyl-1<i>H</i>-imidazo[4,5-<i>b</i>]pyridin-2(3<i>H</i>)-one
C8H8BrN3O
Acta Crystallographica Section E (2010) 66, 8 o1904
a=21.7981(4)Å b=3.99290(10)Å c=20.6636(3)Å
α=90.00° β=95.3980(10)° γ=90.00°
<i>N</i>'-(1-Allyl-2-oxoindolin-3-ylidene)benzohydrazide
C18H15N3O2
Acta Crystallographica Section E (2010) 66, 8 o1905
a=7.5921(2)Å b=15.1968(4)Å c=12.8716(3)Å
α=90.00° β=94.481(2)° γ=90.00°
1-Benzyl-3-methylquinoxalin-2(1<i>H</i>)-one
C16H14N2O
Acta Crystallographica Section E (2010) 66, 8 o1922
a=7.4433(2)Å b=17.5444(5)Å c=18.0598(7)Å
α=118.034(2)° β=100.217(2)° γ=92.7260(10)°
Ethyl 2-(2-oxo-4-phenyl-2,3-dihydro-1<i>H</i>-1,5-benzodiazepin-1-yl)acetate
C19H18N2O3
Acta Crystallographica Section E (2010) 66, 8 o2070
a=12.5198(4)Å b=11.7911(3)Å c=11.2058(3)Å
α=90.00° β=97.843(2)° γ=90.00°
1-[2-(2-Oxo-1,3-oxazolidin-3-yl)ethyl]-4-phenyl-1<i>H</i>- 1,5-benzodiazepin-2(3<i>H</i>)-one
C20H19N3O3
Acta Crystallographica Section E (2010) 66, 8 o2080
a=9.0163(5)Å b=11.6671(6)Å c=16.2019(8)Å
α=90.00° β=90.00° γ=90.00°
1,5-Dimethyl-3-[(3-phenyl-4,5-dihydro-1,2-oxazol-5-yl)methyl]- 1<i>H</i>-1,5-benzodiazepine-2,4(3<i>H</i>,5<i>H</i>)-dione
C21H21N3O3
Acta Crystallographica Section E (2010) 66, 11 o2983
a=9.3491(2)Å b=6.97220(10)Å c=27.9201(5)Å
α=90.00° β=93.1570(10)° γ=90.00°
4-(1,3-Benzothiazol-2-yl)-5-methyl-2-phenyl-1-propynyl- 1<i>H</i>-pyrazol-3(2<i>H</i>)-one
C20H15N3OS
Acta Crystallographica Section E (2010) 66, 11 o2843
a=4.82210(10)Å b=9.3698(2)Å c=37.6990(9)Å
α=90.00° β=90.00° γ=90.00°
3-(6-Bromohexyl)-1,5-dimethyl-1<i>H</i>-1,5-benzodiazepine- 2,4(3<i>H</i>,5<i>H</i>)-dione
C17H23BrN2O2
Acta Crystallographica Section E (2010) 66, 11 o2804
a=7.52140(10)Å b=9.3693(2)Å c=23.8686(5)Å
α=90.00° β=91.7500(10)° γ=90.00°
3-(12-Bromododecyl)-1,5-dimethyl-1<i>H</i>-1,5-benzodiazepine- 2,4(3<i>H</i>,5<i>H</i>)-dione
C23H35BrN2O2
Acta Crystallographica Section E (2010) 66, 11 o2805
a=7.59710(10)Å b=10.5032(2)Å c=28.7129(5)Å
α=90.00° β=95.2130(10)° γ=90.00°
1-Allyl-4-(1,3-benzothiazol-2-yl)-5-methyl-2-phenyl- 1<i>H</i>-pyrazol-3(2<i>H</i>)-one
C20H17N3OS
Acta Crystallographica Section E (2010) 66, 11 o2842
a=17.8734(5)Å b=10.4297(2)Å c=18.9578(4)Å
α=90.00° β=90.00° γ=90.00°
3-[2-(1<i>H</i>-Benzimidazol-2-ylsulfanyl)ethyl]-1,3-oxazolidin-2-one
C12H13N3O2S
Acta Crystallographica Section E (2010) 66, 12 o3137
a=8.2580(10)Å b=10.0740(10)Å c=29.201(3)Å
α=90.00° β=90.00° γ=90.00°
7-Chloro-1,5-dipropargyl-1<i>H</i>-1,5-benzodiazepine- 2,4(3<i>H</i>,5<i>H</i>)-dione
C15H11ClN2O2
Acta Crystallographica Section E (2010) 66, 12 o3228
a=10.7755(3)Å b=7.6580(2)Å c=16.7221(5)Å
α=90.00° β=103.6210(10)° γ=90.00°
1-Allyl-3-methyl-3',5'-diphenylspiro[quinoxaline- 2(1<i>H</i>),2'(3'<i>H</i>)-[1,3,4]thiadiazole]
C25H22N4S
Acta Crystallographica Section E (2010) 66, 12 o3227
a=7.92010(10)Å b=10.07130(10)Å c=13.6642(2)Å
α=78.2960(10)° β=81.2770(10)° γ=89.8260(10)°
1,3-Diallyl-5-chloro-1<i>H</i>-benzimidazol-2(3<i>H</i>)-one
C13H13ClN2O
Acta Crystallographica Section E (2011) 67, 2 o520
a=7.88310(10)Å b=15.2481(3)Å c=10.3593(2)Å
α=90.00° β=93.0560(10)° γ=90.00°
1,3,3,5-Tetramethyl-1<i>H</i>-1,5-benzodiazepine-2,4(3<i>H</i>,5<i>H</i>)-dione
C13H16N2O2
Acta Crystallographica Section E (2011) 67, 4 o783
a=7.51120(10)Å b=10.1731(2)Å c=15.8697(3)Å
α=90.00° β=103.6750(10)° γ=90.00°
3-Benzoyl-1,5-dimethyl-1<i>H</i>-1,5-benzodiazepine-2,4(3<i>H</i>,5<i>H</i>)-\ dione
C18H16N2O3
Acta Crystallographica Section E (2011) 67, 4 o849
a=7.78270(10)Å b=23.7595(4)Å c=8.6315(2)Å
α=90.00° β=105.6140(10)° γ=90.00°
5-Nitro-1-<i>n</i>-octyl-1<i>H</i>-benzimidazol-2(3<i>H</i>)-one
C15H21N3O3
Acta Crystallographica Section E (2011) 67, 3 o558
a=4.9997(3)Å b=11.4942(6)Å c=13.8739(7)Å
α=74.214(3)° β=79.637(4)° γ=84.108(4)°
1-<i>n</i>-decyl-5-nitro-1<i>H</i>-benzimidazol-2(3<i>H</i>)-one
C17H25N3O3
Acta Crystallographica Section E (2011) 67, 3 o613
a=5.4933(2)Å b=10.3063(4)Å c=16.1655(6)Å
α=106.504(2)° β=98.545(2)° γ=96.809(2)°
<i>rac</i>-(3<i>S</i>,4<i>S</i>)-3-Hydroxy-4-phenyl-1-[(<i>S</i>)-(3-phenyl- 4,5-dihydro-1,2-oxazol-5-yl)methyl]-4,5-dihydro-1<i>H</i>-1,5-benzodiazepin- 2(3<i>H</i>)-one
C25H23N3O3
Acta Crystallographica Section E (2011) 67, 4 o945-o946
a=8.981(2)Å b=9.044(2)Å c=13.6850(10)Å
α=95.373(10)° β=102.433(10)° γ=100.03(2)°
1,3-Dibenzyl-1<i>H</i>-anthra[1,2-<i>d</i>]imidazole-2,6,11(3<i>H</i>)-trione
C29H20N2O3
Acta Crystallographica Section E (2011) 67, 5 o1253-o1254
a=8.1389(3)Å b=12.8748(4)Å c=21.5528(8)Å
α=90.00° β=90.00° γ=90.00°
3-[2-(6-Bromo-2-phenyl-3<i>H</i>-imidazo[4,5-<i>b</i>]pyridin- 3-yl)ethyl]-1,3-oxazolidin-2-one
C17H15BrN4O2
Acta Crystallographica Section E (2011) 67, 5 o1095
a=11.3553(6)Å b=11.5915(5)Å c=12.2542(8)Å
α=90.00° β=98.685(6)° γ=90.00°
3-{2-[(3-Phenylquinoxalin-2-yl)oxy]ethyl}-1,3-oxazolidin-2-one
C19H17N3O3
Acta Crystallographica Section E (2011) 67, 5 o1235
a=10.1392(4)Å b=9.1398(4)Å c=34.8462(15)Å
α=90.00° β=90.00° γ=90.00°
1-allyl-3-phenylquinoxalin-2(1<i>H</i>)-one
C17H14N2O
Acta Crystallographica Section E (2011) 67, 11 o2990
a=15.123(2)Å b=7.0390(10)Å c=26.405(3)Å
α=90.00° β=95.250(10)° γ=90.00°
1-Decyl-6-nitro-1<i>H</i>-benzimidazol-2(3<i>H</i>)-one
C17H25N3O3
Acta Crystallographica Section E (2011) 67, 11 o2937
a=32.9827(6)Å b=4.55881(9)Å c=29.3435(5)Å
α=90.00° β=109.481(2)° γ=90.00°
1,3-Bis[2-hydroxy-2-(6-methoxy-2,2-dimethyl-3a,5,6,6a-tetrahydro-2<i>H</i>- furo[2,3-<i>d</i>][1,3]dioxol-5-yl)ethyl]-2,3-dihydro-1<i>H</i>- 1,3-benzodiazol-2-one
C27H38N2O11
Acta Crystallographica Section E (2012) 68, 2 o351
a=30.5551(8)Å b=5.31320(10)Å c=17.8757(5)Å
α=90.00° β=98.267(2)° γ=90.00°
2-Hydroxy-2,3,5,10,11,11a-hexahydro-1<i>H</i>-pyrrolo[2,1- <i>c</i>][1,4]benzodiazepine-5,11-dione
C12H12N2O3
Acta Crystallographica Section E (2011) 67, 8 o1906
a=4.8366(2)Å b=25.7449(11)Å c=8.5420(4)Å
α=90.00° β=96.509(2)° γ=90.00°
4-(Prop-2-ynyl)-2<i>H</i>-1,4-benzothiazin-3(4<i>H</i>)-one
C11H9NOS
Acta Crystallographica Section E (2014) 70, 6 o641
a=9.005(2)Å b=10.889(3)Å c=10.341(3)Å
α=90.00° β=104.565(7)° γ=90.00°
(2<i>Z</i>)-2-Benzylidene-4-<i>n</i>-utyl-3,4-dihydro-2<i>H</i>-1,4-benzothiazin-3-one
C19H19NOS
Acta Crystallographica Section E (2014) 70, 6 o686
a=8.7717(13)Å b=8.8631(13)Å c=12.3184(16)Å
α=88.283(9)° β=82.302(9)° γ=60.895(8)°
<i>N</i>'-(3-Methylquinoxalin-2-yl)-<i>N</i>'-phenylbenzohydrazide
C22H18N4O
Acta Crystallographica Section E (2011) 67, 6 o1374
a=18.6809(12)Å b=10.5840(8)Å c=9.5860(6)Å
α=90.00° β=100.108(3)° γ=90.00°
1-Acetyl-6-bromo-1<i>H</i>-imidazo[4,5-<i>b</i>]pyridin-2(3<i>H</i>)-one
C8H6BrN3O2
Acta Crystallographica Section E (2011) 67, 6 o1375
a=4.8302(15)Å b=9.645(3)Å c=9.809(3)Å
α=81.542(7)° β=85.735(7)° γ=89.676(8)°
Ethyl 8-amino-6-bromoimidazo[1,2-<i>a</i>]pyridine-2-carboxylate
C10H10BrN3O2
Acta Crystallographica Section E (2011) 67, 6 o1390
a=8.366(2)Å b=11.842(3)Å c=22.743(5)Å
α=90.00° β=98.328(6)° γ=90.00°
6-Bromo-3-methyl-2-phenyl-3<i>H</i>-imidazo[4,5-<i>b</i>]pyridine
C13H10BrN3
Acta Crystallographica Section E (2011) 67, 7 o1684
a=13.7138(4)Å b=6.7088(2)Å c=25.3217(7)Å
α=90.00° β=90.00° γ=90.00°
1,3-Dibenzyl-5-chloro-1<i>H</i>-benzimidazol-2(3<i>H</i>)-one
C21H17ClN2O
Acta Crystallographica Section E (2011) 67, 8 o2136
a=11.0380(4)Å b=9.2863(3)Å c=33.2679(13)Å
α=90.00° β=92.297(2)° γ=90.00°
1,3-Bis[3-(1,3-dioxoisoindolin-2-yl)propyl]-1<i>H</i>- anthra[1,2-<i>d</i>]imidazole-2,6,11(3<i>H</i>)-trione
C37H26N4O7
Acta Crystallographica Section E (2011) 67, 8 o2137
a=8.4278(2)Å b=13.1258(3)Å c=13.7966(3)Å
α=94.3590(10)° β=92.4720(10)° γ=105.3510(10)°
5-(Pyridin-4-ylmethyl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin- 4(5<i>H</i>)-one
C11H9N5O
Acta Crystallographica Section E (2011) 67, 8 o1926
a=4.6371(3)Å b=19.2731(10)Å c=5.8593(3)Å
α=90.00° β=102.498(2)° γ=90.00°
1,1'-Dibenzyl-5,5''-dichloro-1,1'',2,2''-tetrahydrodispiro[indole-3,7'- [6,9]diazatricyclo[7.3.0.0^2,6^]dodecane-8',3''-indole]-2,2''-dione
C38H34Cl2N4O2
Acta Crystallographica Section E (2012) 68, 6 o1664
a=12.0421(2)Å b=16.9085(2)Å c=15.9316(2)Å
α=90.00° β=101.2430(10)° γ=90.00°
1-Phenyl-3<i>H</i>-2,3-benzodiazepin-4(5<i>H</i>)-one
C15H12N2O
Acta Crystallographica Section E (2012) 68, 8 o2443
a=5.47180(10)Å b=8.40200(10)Å c=26.3250(5)Å
α=90.00° β=90.00° γ=90.00°
5-Nitro-1,3-bis(prop-2-ynyl)-1<i>H</i>-1,3-benzimidazol-2(3<i>H</i>)-one
C13H9N3O3
Acta Crystallographica Section E (2013) 69, 7 o1159
a=20.0988(16)Å b=4.2645(3)Å c=28.669(2)Å
α=90° β=90° γ=90°
1-Allyl-3-benzyl-1<i>H</i>-benzimidazol-2(3<i>H</i>)-one
C17H16N2O
Acta Crystallographica Section E (2013) 69, 9 o1477-o1478
a=9.0667(2)Å b=9.3922(2)Å c=9.6486(2)Å
α=94.2180(10)° β=113.5430(10)° γ=106.2650(10)°